论文部分内容阅读
干扰素是一种天然物质,人们正在广泛研究其对不同血液肿瘤的治疗作用。α_2-于扰素(α_2IF)对多毛细胞白血病的特殊疗效已获证实。对低度恶性的淋巴瘤、皮肤T细胞淋巴瘤、多发性骨髓瘤及慢性粒细胞白血病都有一定的疗效。但对慢性淋巴细胞白血病(CLL)曾被认为没有明显疗效。但应指出,过去那些接受α_2IF治疗的CLL患者,多数为相当晚期且都经过强烈化疗的患者。因此,未获得满意的效果是不足为奇的。本文报道对先前未治疗过的早期的CLL患者采用α_2IF治疗的结果。材料用重组α_2IF对早期的未治疗过的B细胞慢性淋巴细胞白血病(B-CLL)患者10例进行治疗。其中7例为Rai 0期,3例为Ⅰ期患者。重组α_2IF
Interferon is a natural substance that is being widely studied for its therapeutic effect on different blood tumors. The specific therapeutic effect of α_2-interferon (α_2IF) on hairy cell leukemia has been confirmed. Low-grade lymphoma, cutaneous T-cell lymphoma, multiple myeloma and chronic myeloid leukemia have a certain effect. However, chronic lymphocytic leukemia (CLL) was considered no significant effect. However, it should be noted that in the past those patients who received alpha 2IF treatment were mostly patients who were fairly advanced and who had undergone intensive chemotherapy. Therefore, it is not surprising that the unsatisfactory results have been achieved. This article reports the results of treatment with alpha_2IF for previously untreated early CLL patients. Materials Using recombinant α_2IF, 10 patients with early untreated B-cell chronic lymphocytic leukemia (B-CLL) were treated. Seven of them were Rai 0 and three were stage I. Recombinant α_2IF